Literature DB >> 2453096

Epitope analysis of human cytomegalovirus glycoprotein complexes using murine monoclonal antibodies.

N O Lussenhop1, R Goertz, M Wabuke-Bunoti, R Gehrz, B Kari.   

Abstract

A panel of 10 monoclonal antibodies reactive with human cytomegalovirus (HCMV) glycoproteins was generated. These antibodies immunoprecipitated disulfide-linked complexes which contained glycoproteins with molecular weights of 130,000, 93,000, and 52,000. These complexes were designated gC-I. Epitope analysis of gC-I was done with a simultaneous two antibody binding assay. A network of epitopes was revealed which clustered in three major domains designated I, II, and III. Antibodies within individual domains I and II showed strong mutual inhibition of each other's binding. However, there were multiple antibody interactions between domains I and II. For example, the binding of most antibodies in domain I was augmented to some extent by antibodies from domain II. However, the binding of only one antibody from domain II was augmented by all antibodies from domain I. The augmentation in binding between two antibodies was dependent on the native structure of gC-I and was sensitive to conformational changes due to nonionic detergent extraction of gC-I and/or disruption of disulfide bonds. A synergistic effect was also observed between antibodies in domains I and II in a virus neutralization assay. A neutralizing antibody had a much greater neutralizing activity in the presence of a nonneutralizing antibody, which also enhanced the binding of the neutralizing antibody in the simultaneous two antibody binding assay. Also, two antibodies which were nonneutralizing individually were neutralizing when used in combination. Such antibodies also augmented each other's binding in the simultaneous two antibody binding assay. Finally, domain III consisted of a nonneutralizing antibody that inhibited the binding of all antibodies in domains I and II. This antibody also inhibited the neutralizing activity of a neutralizing antibody in a virus neutralizing assay.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2453096     DOI: 10.1016/0042-6822(88)90549-1

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus.

Authors:  B Wagner; B Kropff; H Kalbacher; W Britt; V A Sundqvist; L Ostberg; M Mach
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

2.  Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies.

Authors:  T G Besselaar; N K Blackburn
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

3.  The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins.

Authors:  T G Besselaar; N K Blackburn
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites.

Authors:  J A Simpson; J C Chow; J Baker; N Avdalovic; S Yuan; D Au; M S Co; M Vasquez; W J Britt; K L Coelingh
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

5.  Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus.

Authors:  U Utz; W Britt; L Vugler; M Mach
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Mapping and characterization of neutralizing epitopes of glycoproteins gIII and gp50 of the Indiana-Funkhauser strain of pseudorabies virus.

Authors:  N E Coe; W L Mengeling
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

7.  Analysis of human antibody responses to human cytomegalovirus envelope glycoproteins found in two families of disulfide linked glycoprotein complexes designated gC-I and gC-II.

Authors:  B Kari; R Gehrz
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

8.  Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne.

Authors:  R R Spaete; A Saxena; P I Scott; G J Song; W S Probert; W J Britt; W Gibson; L Rasmussen; C Pachl
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

9.  Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response.

Authors:  W J Britt; L Vugler; E J Butfiloski; E B Stephens
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

10.  Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.

Authors:  F Verrier; A Nádas; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.